Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Current Assets (2016 - 2025)

Historic Current Assets for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $43.8 million.

  • Harvard Bioscience's Current Assets fell 638.16% to $43.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.8 million, marking a year-over-year decrease of 638.16%. This contributed to the annual value of $45.1 million for FY2024, which is 799.58% down from last year.
  • As of Q3 2025, Harvard Bioscience's Current Assets stood at $43.8 million, which was down 638.16% from $45.0 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Current Assets registered a high of $61.6 million during Q4 2021, and its lowest value of $43.8 million during Q3 2025.
  • Over the past 5 years, Harvard Bioscience's median Current Assets value was $50.5 million (recorded in 2023), while the average stood at $50.7 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 2795.5% in 2021, then crashed by 1698.36% in 2022.
  • Quarter analysis of 5 years shows Harvard Bioscience's Current Assets stood at $61.6 million in 2021, then dropped by 16.98% to $51.1 million in 2022, then decreased by 4.08% to $49.0 million in 2023, then fell by 8.0% to $45.1 million in 2024, then fell by 2.91% to $43.8 million in 2025.
  • Its last three reported values are $43.8 million in Q3 2025, $45.0 million for Q2 2025, and $44.9 million during Q1 2025.